Slide 1: Obesity KOL Webinar: ARO-INHBE and ARO-ALK7 Interim Phase 1/2a Clinical Data
Obesity KOL Webinar ARO-INHBE and ARO-ALK7 Interim Phase 1/2a Clinical Data January 06, 2026
Slide 2: Introduction and Agenda
Introduction and Agenda Vince Anzalone, CFA Vice President, Finance and IR ARO-INHBE and ARO-ALK7 Interim Clinical Data Update January 2026
Slide 3: Safe Harbor Statement
3 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results
Slide 4: Agenda
4 Agenda Topic Presenter Introduction Vince Anzalone, CFA The Future: What’s Next in Obesity Treatment to Address the Unmet Needs Carel Le Roux, M.D., Ph.D. University College Dublin, School of Medicine Therapeutic Rationale for Targeting the Activin E - ALK7 Axis James Hamilton, M.D., MBA Interim R
Slide 5: Obesity Key Opinion Leader Carel le Roux
5 Obesity Key Opinion Leader Carel le Roux, M.D., Ph.D. Chair of Metabolic Medicine, University College Dublin, School of Medicine Professor Carel le Roux graduated from medical school in Pretoria South Africa, completed his specialist training in metabolic medicine and obtained his PhD from Imperia
Slide 6: The Future: What's Next in Obesity Treatment to Address the Unmet Needs
The Future: What’s Next in Obesity Treatment to Address the Unmet Needs Carel le Roux, M.D., Ph.D. University College Dublin, Ulster University, University of Pretoria Joseph Wright of Derby. The Alchemist Discovering Phosphorus. 1771. Derby Museum and Art Gallery
Slide 7: Conflicts of Interest
7 Conflicts of Interest • Consilient Health • Novo Nordisk • Herbalife • Johnson & Johnson • Covidien • Fractyl • GI Dynamics • Olympus • Lilly • Boehringer Ingelheim • Keyron • Astra Zeneca • Roche • Arrowhead • Amgen
Slide 8: Death from Cardiovascular Disease
8 Death from Cardiovascular Disease Rawshani et al. NEJM 2017. 0 50 100 150 200 250 '98–'99 '00–'01 '02–'03 '04–'05 '06–'07 '08–'09 '10–'11 '12–'13 Patients with Type 2 Diabetes Matched Controls Standardized Incidence Rate (per 10,000 person-yr)
Slide 9: Visceral Fat Drives Metabolic Diseases
9 Visceral Fat Drives Metabolic Diseases
Slide 10: What We Know: Risk Doesn't Always Follow BMI
10 Obesity e.g, CVD Risk What We Know: Risk Doesn’t Always Follow BMI Coral, le Roux et al Nature Medicine 2024. Discordant Individuals
Slide 11: Discordant Profiles and Disease Prevalence
11 DIS: Discordant Inflammatory state profile DHG: Discordant Hyperglycaemic profile DAL: Discordant Adverse Lipid profile BC: Baseline Concordant profile DLT: Discordant Liver Transaminases profile DLT: Discordant Liver Transaminases profile BC: Baseline Concordant profile DAL: Discordant Adverse L
Slide 12: Emergence of Highly Effective Obesity Medications
12 Gen 1 Gen 2 Gen 3 Intensive Lifestyle Therapy Bariatric Surgery Emergence of Highly Effective Obesity Medications Kaplan LM, 2023. 0% 5% 10% 15% 20% 25% 30% 35% 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2021 2023 (est.) Semaglutide 2.4 mg Tirzepatide 10–15 mg* Year M a x im
Slide 13: Weight Reduction from Baseline to Week 72
13 Weight Reduction from Baseline to Week 72: Percent Change ***p<0.001 vs semaglutide. Data are LSM ± 95% CI. Data from Aronne LJ, le Roux CW et al. N Engl J Med 2025 TRE = Treatment-regimen estimand. Weight Change from Baseline (%) Semaglutide 2.4 mg or MTD Tirzepatide 15 mg or MTD -25% -20% -15%
Slide 14: Proposed Obesity Treat to Target Thresholds
14 Proposed Obesity Treat to Target Thresholds ASCVD = Atherosclerotic cardiovascular disease; BMI = body mass index; HTN = hypertension; OA = osteoarthritis; ORC = obesity-related complication; T2D = type 2 diabetes; WHtR = waist to height ratio. Busetto L, et al. AS07.02. Obes Facts 2024; 17 (supp
Slide 15: Participants Reaching Treat to Target Thresholds at Week 72
15 20.0 20.7 14.2 33.9 29.9 23.1 0 10 20 30 40 50 BMI <27 kg/m WHtR <0.53 BMI <27 kg/m and WHtR <0.53 Percent of Participants Reaching Treat to Target Thresholds at Week 72 **p<0.01 vs semaglutide. ***p<0.001 vs. semaglutide. Note: Week 72 data in participants who discontinued study drug early was i
Slide 16: Normalization of Cardiometabolic Parameters
16 Percent of Participants with Normalization of Cardiometabolic Parameters Baseline Normoglycemia (HbA1c <5.7% and FSG <100 mg/dL). HDL sex-specific goals (female ≥50 mg/dL, male ≥40 mg/dL). Data are means based on observed data at baseline for participants who completed treatment. 43 70 58 29 70 3
Slide 17: Normalization of Cardiometabolic Parameters at WHtR <0.53 & BMI <27
17 Normalization of Cardiometabolic Parameters in Participants Reaching WHtR <0.53 & BMI <27 at Week 72 Normoglycemia (HbA1c <5.7% and FSG <100 mg/dL). HDL sex-specific goals (female ≥50 mg/dL, male ≥40 mg/dL). N = number of participants meeting WHtR <0.53 and BMI <27 kg/m2 at Week 72. Data are mean
Slide 18: Patients with Diabetes Lose Less Weight
18 Patients with Diabetes Lose Less Weight Percent Change in Bodyweight at 72 weeks (efficacy estimand) Overall mean baseline weight = 104.8 kg Overall mean baseline weight = 100.8 kg -2.4 -16 -21.4 -22.5 -3.3 -13.4 -15.7 -25 -20 -15 -10 -5 0 SURMOUNT-1 (No TD2M) SURMOUNT-2 (T2DM) NEJM 2022 Lancet 2
Slide 19: Pipeline: By Phase, MOA, and Administration Route
19 Pipeline: By Phase, MOA, and Administration Route Source: IQVIA Analytics Link; Cinicaltraials.gov; company reports, press releases, desk research, IQVIA EMEA Thought Leadership analysis; December 2024. GLP-1 = glucagon-like peptide 1; GIP = gastric inhibitory polypeptide; GCG = glucagon; MoA = m
Slide 20: Therapeutic Potential for RNAi-based Targeting of the Activin E-ALK7 Pathway
20 Therapeutic Potential for RNAi-based Targeting of the Activin E – ALK7 Pathway 20% 9% 5% 4% 4% 36% 8% GLP-1 GLP-1/GIP Activin/Myostatin Amylin GLP-1/Glucagon 3% – GLP-1/GIP/Glucagon 3% – GLP-1/Amylin 2% – GLP-1/FGF21 CB1– 2% NLRP3 – 2% Ghrelin – 1% Leptin – 1% Not Specified Novel mechanism of act
Slide 21: Conclusions
21 Conclusions Recognising the different subtypes of obesity The Future of Obesity Care Will Include Reducing visceral fat to achieve better cardio-kidney- metabolic outcomes Combining therapies to achieve low cardiovascular risk state
Slide 22: Therapeutic Rationale for Targeting the Activin E-ALK7 Axis
Therapeutic Rationale for Targeting the Activin E – ALK7 Axis James Hamilton MD, MBA Chief Medical Officer and Head of R&D ARO-INHBE and ARO-ALK7 Interim Clinical Data Update
Slide 23: Targeting Visceral Adiposity to Improve Metabolic Health
23 Targeting Visceral Adiposity to Improve Metabolic Health 1. Neeland et al., Lancet Diabetes Endocrinol 2019; 2. Stefan et al., Lancet Diabetes Endocrinol 2020; 3. Linge et al., Surg Obes Relat Dis 2024; 4. Abdullah et al., Frontiers in endocrinology 2025; 5. Okauchi et al., Diabetes Care 2007 Sys
Slide 24: Hepatic Activin E Regulates Energy Homeostasis via the ALK7 Receptor
24 Hepatic Activin E Encoded by INHBE Gene Regulates Energy Homeostasis in Adipose Tissue via the ALK7 Receptor 1. Deaton et al., Nat Commun 2022; 2. Akbari et al., Nat Commun 2022. NEFA = non-esterified fatty acids Excess caloric intake Activin E Hepatocyte Liver tissue Adipose tissue Adipocyte Lip
Slide 25: pLOF Variants of INHBE Associated with Reduced Abdominal Fat and Cardiometabolic Risk
25 Trait Beta (95% CI) Triglycerides1 -0.13 (-0.21, -0.05) HDL-C1 0.10 (0.02, 0.18) Apolipoprotein B1 -0.076 (-0.16, 0.004) Fasting Glucose1 -0.17 (-0.33, -0.02) HgbA1c2 -0.053 (-0.11, 0.001) ALT2 -0.07 (-0.13, -0.02) WHR Adjusted for BMI1 -0.22 (-0.3, -0.14) Visceral Fat Volume (MRI)2 -0.23 (-0.45,
Slide 26: Silencing Hepatic INHBE May Inhibit Maladaptive Activin E-ALK7 Signaling
26 Silencing Hepatic INHBE May Inhibit Maladaptive Activin E – ALK7 Signaling and Improve Adipose Dysfunction in Obesity 1. Deaton et al., Nat Commun 2022; 2. Akbari et al., Nat Commun 2022. NEFA = non-esterified fatty acids Excess caloric intake INHBE gene silenced Activin E production inhibited He
Slide 27: Clinical Study Update from AROINHBE-1001
Clinical Study Update from AROINHBE-1001 James Hamilton MD, MBA Chief Medical Officer and Head of R&D ARO-INHBE and ARO-ALK7 Interim Clinical Data Update
Slide 28: AROINHBE-1001: Phase 1/2a Study Design
28 AROINHBE-1001: Phase 1/2a Study of ARO-INHBE in Volunteers with Obesity, with and without Type 2 Diabetes Mellitus MAD = Multiple Ascending Dose; SAD = Single Ascending Dose; T2DM = Type 2 Diabetes Mellitus; TZP = Tirzepatide Cohort 2b (100 mg ARO-INHBE) (n=12) Cohort 2c (100 mg ARO-INHBE + TZP 5
Slide 29: Key Endpoints
29 Key Endpoints MRI = Magnetic Resonance Imagine; MRI-PDFF = Magnetic Resonance Imaging-Proton Density Fat Fraction Safety Pharmacokinetics Exploratory 1° 2° • Serum Activin E • Weight change (kg/%) • Body adiposity, adipose distribution, fat mass vs lean mass (MRI) • Liver fat content (MRI-PDFF) •
Slide 30: Baseline Characteristics – Participants with Obesity (Monotherapy)
30 Baseline Characteristics – Participants with Obesity (Monotherapy) BMI = Body Mass Index; HgbA1c = Hemoglobin A1c; MAD = Multiple Ascending Dose; SAD = Single Ascending Dose; SD = Standard Deviation ARO-INHBE SAD Cohorts (N=25) ARO-INHBE MAD Cohorts (N=36) Age, mean (SD) 43 (8.8) 41.6 (11.7) Sex,
Slide 31: ARO-INHBE Achieved Mean Max Activin E Reduction of 85%
31 ARO-INHBE Achieved Mean Max Activin E Reduction of 85% with Long Response Duration 0 2 4 6 8 10 12 14 16 -100 -80 -60 -40 -20 0 20 40 Study Week M e a n P e rc e n t C h a n g e fr o m B a s e li n e ( ± S D ) Placebo ARO-INHBE 50 mg ARO-INHBE 100 mg ARO-INHBE 200 mg ARO-INHBE 400 mg
Slide 32: Single Dose Achieved Visceral Fat Reductions of 9.9% and Liver Fat Reductions
32 A Single Dose of ARO-INHBE Achieved Mean Visceral Fat Reductions of 9.9% and Liver Fat Reductions of up to 38.6% Body composition measurements obtained using MRI. 1. Visceral adipose tissue in the abdominal cavity; 2. Liver fat measured using MRI-PDFF; 3. Total lean tissue measured from neck to k
Slide 33: Repeat Doses Enhanced Placebo Adjusted Visceral Fat Reductions to 15.6%
33 Week 12 Week 24 -20 -15 -10 -5 0 5 10 Visceral Adipose Tissue (MRI) Study Week M e a n P e rc e n t C h a n g e f ro m B a s e li n e (± S D ) Repeat Doses of ARO-INHBE Enhanced Mean Placebo Adjusted Visceral Fat Reductions to 15.6% Body composition measurements obtained using MRI. 1. Visceral ad
Slide 34: Combination Therapy Update – Obesity with Type 2 Diabetes Mellitus
Combination Therapy Update – Obesity with Type 2 Diabetes Mellitus
Slide 35: Baseline Characteristics – Obesity and Type 2 Diabetes (Combination with Tirzepatide)
35 Baseline Characteristics – Participants with Obesity and Type 2 Diabetes Mellitus (Combination with tirzepatide) BMI = Body Mass Index; HgbA1c = Hemoglobin A1c; MAD = Multiple Ascending Dose; SAD = Single Ascending Dose; SD = Standard Deviation Participants with Obesity and T2DM (N=24) Age, mean
Slide 36: Insulin Resistance is Associated with Higher Activin E Levels
36 Non-Diabetic Diabetic 0 500 1000 1500 A c ti v in E ( p g /m L ) Insulin Resistance is Associated with Higher Activin E Levels in Primates and in Humans 1. Sugiyama et al., PLOS ONE 2018 Healthy Diabetic 0 50 100 150 200 250 A c ti v in E ( p M ) Non-Human Primates AROINHBE-1001 Participants Diab
Slide 37: Baseline Activin E Levels Correlate with Insulin Resistance and Anthropometric Measures
37 Baseline Activin E Levels Correlate with Insulin Resistance and Anthropometric Measures in Study Participants with Diabetes BMI (kg/m2)HOMA-IR (%) Waist Circumference (cm) Diabetes No Diabetes 0 5 10 15 20 25 0 300 600 900 1200 A c ti v in E ( p g /m L ) r=0.65 r=0.40 25 30 35 40 45 50 55 0 300 6
Slide 38: Patients with Obesity and T2DM Lose Less Weight on Incretins
38 Patients with obesity and type 2 diabetes mellitus experience less weight loss and are less likely to reach weight loss targets with incretin therapy Patients with Obesity and Type 2 Diabetes Lose Less Weight On Incretins and Need More Therapeutic Options 1. Ludvik et al., Lancet 2021; 2. Jastreb
Slide 39: Preclinical Studies Indicate Enhanced Weight Loss with INHBE Silencing plus Tirzepatide
39 8 15 22 29 36 43 50 57 64 -20 -10 0 10 20 30 %BW change Study Day % B W c h a n g e Saline INHBE (9 mpk) Tirzepatide (0.48 mpk) INHBE + Tirzepatide (0.48 mpk) % B W C h a n g e Study Preclinical Studies Indicate Enhanced Weight Loss with INHBE Silencing Combined with tirzepatide in Diabetic Mice
Slide 40: Durable Decreases in Serum Activin E up to 84% in T2DM Combination Cohorts
40 ARO-INHBE Demonstrated Substantial and Durable Decreases in Serum Activin E up to 84% in T2DM Combination Cohorts. No Decrease in Activin E with Tirzepatide Alone. QW = Once weekly dosing; T2DM = Type 2 Diabetes Mellitus; TZP = Tirzepatide Obesity with T2DM Combination Therapy Cohorts ARO-INHBE 4
Slide 41: Combination Therapy Enhanced Weight Loss Compared to Tirzepatide Alone
41 0 2 4 6 8 10 12 14 16 18 20 22 24 -12.5 -10.0 -7.5 -5.0 -2.5 0.0 2.5 5.0 7.5 10.0 Study Week M e a n P e rc e n t C h a n g e fr o m B a s e li n e (± S D ) Combination Therapy with ARO-INHBE Enhanced Weight Loss Compared to Tirzepatide Alone in Obese T2DM Patients QW = Once weekly dosing; T2DM =
Slide 42: Combination Therapy Achieved Synergistic Fat Loss
42 Week 12 -100 -80 -60 -40 -20 0 Study Week M e a n P e rc e n t C h a n g e f ro m B a s e li n e (± S D ) Liver Fat Content (MRI-PDFF) Week 12 -25 -20 -15 -10 -5 0 Total Adipose Tissue Study Week M e a n P e rc e n t C h a n g e f ro m B a s e li n e (± S D ) Week 12 -30 -20 -10 0 Study Week M e
Slide 43: Fat Reductions with ARO-INHBE + Low-dose TZP Compare Favorably with High-dose TZP
43 Visceral Fat and Liver Fat Reductions with ARO-INHBE + Low-dose TZP Compare Favorably with High-dose TZP at 52 Weeks in SURPASS-3 1. Gastaldelli et al., Diabetes & endocrinology 2022; ASAT = Abdominal Subcutaneous Adipose Tissue; TZP = Tirzepatide; VAT = Visceral Adipose Tissue % Reduction AROINH
Slide 44: Targeting Activin E May Be More Effective in Insulin Resistance
44 Targeting Activin E may be More Effective in Conditions of Insulin Resistance: A Plausible Hypothesis Guilherme et al., Trends Cell Biol 2023. T2DM = Type 2 Diabetes Mellitus Activin EInsulin is a potent inhibitor of lipolysis in adipose tissue In conditions of insulin resistance or reduced insul
Slide 45: ARO-INHBE Demonstrates a Favorable Safety Profile
45 ARO-INHBE Demonstrates a Favorable Safety Profile ARO-INHBE was well tolerated as monotherapy and in combination with tirzepatide in participants with obesity with and without type 2 diabetes. • Most TEAEs were mild in severity • No TEAEs led to study or study drug discontinuation Injection site
Slide 46: Stable Liver and Glycemic Parameters in Monotherapy Groups
46 0 2 4 6 8 10 12 14 16 18 20 22 24 2 4 6 8 Study Week M e a n H b A 1 c ( % ) (± S D ) Stud ek 0 2 4 6 8 10 12 14 16 0 10 20 30 40 Study Week M e a n A L T (U /L ) (± S D ) 0 2 4 6 8 10 12 14 16 0 10 20 30 40 Study Week M e a n A L T (U /L ) (± S D ) Stable Liver and Glycemic Parameters in Monothe
Slide 47: Stable Liver Chemistries and Improving Glycemic Parameters in Combination Groups
47 0 2 4 6 8 10 12 14 16 18 20 22 24 10 20 30 40 50 60 Study Week M e a n A L T ( U /L ) (± S D ) 0 2 4 6 8 10 12 14 16 18 20 22 24 5 6 7 8 Study Week M e a n H b A 1 c ( % ) (± S D ) Stable Liver Chemistries and Improving Glycemic Parameters in Combination Therapy Groups ALT = Alanine Aminotransfer
Slide 48: Summary and Next Steps
48 Summary and Next Steps HbA1c = Hemoglobin A1c ARO-INHBE was safe, well-tolerated, and achieved robust and sustained reductions in serum Activin E levels with no adverse changes in transaminases or HbA1c Monotherapy with ARO-INHBE achieved meaningful reductions in visceral and liver fat by MRI Com
Slide 49: Clinical Study Update from AROALK7-1001
Clinical Study Update from AROALK7-1001 James Hamilton MD, MBA Chief Medical Officer and Head of R&D ARO-INHBE and ARO-ALK7 Interim Clinical Data Update
Slide 50: ALK7 is a Genetically Validated Adipose Target
50 ARO-ALK7 Excess caloric intake Increased INHBE expression Activin E ALK7 production inhibited Lipolysis Circulating NEFA Adipose hypertrophy & dysfunction Visceral adiposity Insulin resistance Other ALK7 ligands ALK7 mRNA silenced Increased TG Activin Receptor-like Kinase 7 (ALK7, ACVR1C) is a Ge
Slide 51: AROALK7-1001: Phase 1/2a Study Design
51 AROALK7-1001: Phase 1/2a Study of ARO-ALK7 in Volunteers with Obesity, with and without Type 2 Diabetes Mellitus MAD = Multiple Ascending Dose; SAD = Single Ascending Dose; T2DM = Type 2 Diabetes Mellitus; TZP = Tirzepatide Cohort 3b (100 mg ARO-ALK7) (n=12) Cohort 3c (100 mg ARO-ALK7 + TZP 5 mg
Slide 52: Key Endpoints
52 Key Endpoints MRI = Magnetic Resonance Imagine; MRI-PDFF = Magnetic Resonance Imaging-Proton Density Fat Fraction Safety Pharmacokinetics Exploratory 1° 2° • Adipose Expression of ALK7 • Weight change (kg/%) • Waist circumference • Body adiposity, adipose distribution, fat mass vs lean mass (MRI)
Slide 53: Baseline Characteristics – Volunteers with Obesity (Part 1)
53 Baseline Characteristics – Volunteers with Obesity (Part 1) BMI = Body Mass Index; HgbA1c = Hemoglobin A1c; MAD = Multiple Ascending Dose; SAD = Single Ascending Dose; SD = Standard Deviation ARO-ALK7 SAD Cohorts (N=30) ARO-ALK7 MAD Cohorts (N=24) Age, mean (SD) 39.0 (13.1) 39.6 (9.5) Sex, female
Slide 54: ARO-ALK7 Dose Dependent Decreases in Alk7 mRNA up to 88%
54 0 4 8 12 -100 -80 -60 -40 -20 0 20 40 Study Week M e a n P e rc e n t C h a n g e f ro m B a s e li n e ( ± S D ) ARO-ALK7 Demonstrated Dose Dependent Mean Decreases in Alk7 mRNA up to 88%, Confirming TRiM Platform Ability to Silence Adipocyte Gene Expression 88% Placebo ARO-ALK7 10 mg ARO-ALK7 3
Slide 55: Rapid Dose-dependent Reductions in Visceral Fat After a Single Dose
55 Rapid Dose-dependent Reductions in Visceral Fat of Up to 14.1% (Placebo-adjusted) After a Single Dose of ARO-ALK7 Placebo ARO-ALK7 10 mg ARO-ALK7 30 mg ARO-ALK7 100 mg ARO-ALK7 200 mg Week 8 -20 -15 -10 -5 0 5 Visceral Adipose Tissue Study Week M e a n P e rc e n t C h a n g e f ro m B a s e li n
Slide 56: ARO-ALK7 Demonstrated a Favorable Safety Profile
56 Most TEAEs were mild in severity ARO-ALK7 Demonstrated a Favorable Safety Profile No clinically significant adverse laboratory trends (including in liver enzymes and glycemic parameters) were identified. ARO-ALK7 was well tolerated as monotherapy in participants with obesity. No TEAEs led to stud
Slide 57: Summary and Next Steps
57 Summary and Next Steps MAD = Multiple Ascending Dose; SAD = Single Ascending Dose ARO-ALK7 was safe, well-tolerated, and led to deep reductions in adipose ALK7 expression at all clinical doses SAD and MAD Cohorts fully enrolled and Part 2 Cohorts, recruiting participants with obesity with and wit
Slide 58: Thank you to patients, investigators, and site personnel
We would like to thank the patients, investigators, and site personnel who participated in the studies
Slide 59: Key Takeaways
Key Takeaways Chris Anzalone, Ph.D. President and CEO ARO-INHBE and ARO-ALK7 Interim Clinical Data Update January 2026
Slide 60: Key Early Findings from Ongoing Phase 1/2a Studies
60 Key Early Findings from Ongoing Phase 1/2a Studies ➢ ARO-INHBE: dose-dependent reductions in serum Activin E o mean max reduction of -85% after a single 400 mg dose o max observed reduction of -94% ➢ ARO-INHBE + TZP drove high quality weight loss in obese diabetic patients o -23.2% visceral fat r
Slide 61: What We Already Achieved in Phase 1/2a
61 What We Already Achieved in Phase 1/2a Established Safety and Tolerability of single-dose, multi-dose, and combination regimens with tirzepatide Demonstrated deep and durable knockdown of Activin E and ALK7 Identified signals of Activin E/ALK7 pathway translation in humans Measured favorable chan
Slide 62: What We Still Hope to Achieve: Next Steps
62 What We Still Hope to Achieve Next Steps • Expanding current studies, including: • Increasing numbers of patients to increase power • Extending follow-up to better understand drug durability and activity out to 1 year • Initiation of a monotherapy cohort in obese diabetic patients • Initiation of
Slide 63: Obesity Complements our Cardiometabolic Launch Plans
63 Obesity Complements our Cardiometabolic Launch Plans Obesity Next Launch?
Slide 64: Arrowhead's Growth Drivers in 2026 and Beyond
64 Arrowhead’s Growth Drivers in 2026 and Beyond Arrowhead’s first commercial sales of REDEMPLO in familial chylomicronemia ARO-DIMER-PA targeting PCSK9 and APOC3 first clinical readout in 2H 2026 Phase 3 studies of plozasiran in severe hypertriglyceridemia (potential multi-billion-dollar opportunit
Slide 65: Questions?
“oN Questions? () » Answers.